There is room for both biological and synthetic products in the market.
Patients/ medical experts already have a choice between the two, and there are many patients where biological products may be more suitable.
Why not have a product portfolio that offer both types of products.
The forecast revenue of ARX is not that far behind PNV for the next few years, proving that there is a market for biological products.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.23 |
Change
-0.030(2.38%) |
Mkt cap ! $849.7M | |||
| Open | High | Low | Value | Volume |
| $1.25 | $1.25 | $1.22 | $1.124M | 914.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4500 | $1.23 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.24 | 16326 | 1 |
View Market Depth
| Last trade - 16.13pm 21/07/2025 (20 minute delay) ? |
| PNV (ASX) Chart |